MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment

By J. Bernhagen, Regina M. Krohn, H. Lue, Julia L. Gregory, A. Zernecke, R. Koenen, M. Dewor, Ivan T. Georgiev, A. Schober, L. Leng and 8 more. Nature Medicine, 2007

1,285 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Immunology

View Paper: https://www.semanticscholar.org/paper/87a8f75fade9f80f0d85bf003bc42b28469c050b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. A. Schober

In Immunology

1. A. Zlotnik
2. O. Yoshie
3. Caroline L. Sokol
4. A. Luster
5. Peter Libby
6. Christian Weber
7. C. Shi
8. Eric G. Pamer

Citations in the corpus

• Atherosclerosis: current pathogenesis and therapeutic options (2011, background): “Notably, neutralizing the noncanonical chemokine macrophage migration inhibitory factor (MIF) caused regression of established lesions, probably because of its CXCR2 and CXCR4 agonist effect, which promoted macrophage and T-cell infiltratio”
• Monocyte recruitment during infection and inflammation (2011, background): “CXCR2 mediates monocyte arrest that is induced by macrophage migration inhibitory factor (MIF”
• International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors (2014, neutral): “product N-acetyl-proline-glycine-proline, macrophage migration inhibitory factor, the N9-terminal domain of human tyrosyl-tRNA synthetase, Brugia malayi asparaginyl-tRNA synthetase, and the HIV matrix protein p17, were suggested to have sequence/charge/structure similarities to ELR CXC chemokines, w”
• The Chemokine Superfamily Revisited (2012, positive): “Macrophage migration inhibitory factor (MIF) is an evolutionary conserved cytokine with proinflammatory functions, and has also been claimed to be a non-canonical CXCR2 and CXCR4 ligand (Bernhagen et al., 2007).”
• The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models (2008, background): “This promotes the recovery of endothelial cells but also the vascularization of the plaque and its infiltration by macrophages by recruiting EPC-like CD14 + cell”
• Delivery of MicroRNA-126 by Apoptotic Bodies Induces CXCL12-Dependent Vascular Protection (2009, methodology): “The extent of atherosclerosis was assessed in aortic roots by detecting lipid deposition with Oil Red O (29, 40, 41) in 5-mm transversal sections.”
• Chemokines and chemokine receptors: positioning cells for host defense and immunity. (2014, background): “and macrophages, leading to CXCR2 signaling and integrin-dependent chemotaxis of monocytes, which is necessary for the maintenance of atherosclerotic plaques (105).”
• The chemokine system in innate immunity. (2015, background): “MIF binds to CD74 and CXCR2 on monocytes and macrophages, leading to CXCR2 signaling and integrin-dependent chemotaxis of monocytes, which is necessary for maintenance of atherosclerotic plaques (Bernhagen et al. 2007).”
• Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets—An Updated View (2013, background): “While the precise signaling mechanisms of MIF through these receptors are yet to be clarified, it was demonstrated that the MIF/CXCR axis is critical for MIF-dependent monocyte recruitment processes in atherosclerotic arteries [75].”